UnitedHealth Group Incorporated (NYSE:UNH) had its target price lifted by equities research analysts at Morgan Stanley from $210.00 to $215.00 in a research note issued on Thursday. The brokerage presently has an “overweight” rating on the healthcare conglomerate’s stock. Morgan Stanley’s target price points to a potential upside of 10.96% from the company’s current price.

A number of other equities analysts have also recently commented on the company. Zacks Investment Research cut UnitedHealth Group from a “buy” rating to a “hold” rating in a report on Friday, May 19th. Deutsche Bank AG reiterated a “buy” rating and issued a $187.00 target price (up previously from $183.00) on shares of UnitedHealth Group in a report on Saturday, April 22nd. Cantor Fitzgerald reiterated an “overweight” rating and issued a $208.00 target price on shares of UnitedHealth Group in a report on Friday, July 21st. Vetr upgraded UnitedHealth Group from a “hold” rating to a “buy” rating and set a $186.50 target price for the company in a report on Tuesday, May 30th. Finally, CIBC lifted their target price on UnitedHealth Group from $186.00 to $187.00 and gave the stock an “outperform” rating in a report on Monday, April 24th. One research analyst has rated the stock with a hold rating and twenty-four have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $202.41.

Shares of UnitedHealth Group (NYSE UNH) traded down 0.10% during mid-day trading on Thursday, reaching $193.57. The company’s stock had a trading volume of 980,269 shares. The stock has a market capitalization of $187.15 billion, a P/E ratio of 23.25 and a beta of 0.64. UnitedHealth Group has a 12-month low of $132.39 and a 12-month high of $196.04. The company’s 50-day moving average price is $190.13 and its 200-day moving average price is $175.54.

UnitedHealth Group (NYSE:UNH) last announced its earnings results on Tuesday, July 18th. The healthcare conglomerate reported $2.46 EPS for the quarter, topping the Zacks’ consensus estimate of $2.38 by $0.08. The firm had revenue of $50.05 billion during the quarter, compared to analysts’ expectations of $49.97 billion. UnitedHealth Group had a return on equity of 21.52% and a net margin of 4.32%. The company’s quarterly revenue was up 7.7% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.96 EPS. On average, equities research analysts forecast that UnitedHealth Group will post $9.87 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This story was originally published by Daily Political and is the property of of Daily Political. If you are reading this story on another publication, it was stolen and republished in violation of U.S. and international copyright & trademark laws. The correct version of this story can be read at https://www.dailypolitical.com/2017/08/17/unitedhealth-group-incorporated-unh-pt-raised-to-215-00-at-morgan-stanley.html.

In other news, Director Gail R. Wilensky sold 5,540 shares of the business’s stock in a transaction on Friday, June 2nd. The stock was sold at an average price of $178.74, for a total value of $990,219.60. Following the completion of the transaction, the director now directly owns 60,516 shares of the company’s stock, valued at approximately $10,816,629.84. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director William C. Ballard, Jr. sold 5,000 shares of the business’s stock in a transaction on Thursday, August 3rd. The stock was sold at an average price of $193.98, for a total value of $969,900.00. Following the completion of the transaction, the director now directly owns 76,058 shares of the company’s stock, valued at $14,753,730.84. The disclosure for this sale can be found here. Over the last three months, insiders sold 15,540 shares of company stock valued at $2,873,320. Corporate insiders own 0.89% of the company’s stock.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. WINTON GROUP Ltd raised its position in UnitedHealth Group by 43.7% in the second quarter. WINTON GROUP Ltd now owns 177,163 shares of the healthcare conglomerate’s stock valued at $32,850,000 after buying an additional 53,880 shares during the last quarter. Covington Capital Management raised its position in UnitedHealth Group by 6.0% in the second quarter. Covington Capital Management now owns 72,411 shares of the healthcare conglomerate’s stock valued at $13,427,000 after buying an additional 4,075 shares during the last quarter. Colony Group LLC raised its position in UnitedHealth Group by 9.2% in the second quarter. Colony Group LLC now owns 133,979 shares of the healthcare conglomerate’s stock valued at $24,842,000 after buying an additional 11,259 shares during the last quarter. Sunbelt Securities Inc. bought a new position in UnitedHealth Group during the second quarter valued at approximately $218,000. Finally, National Asset Management Inc. raised its position in UnitedHealth Group by 16.2% in the second quarter. National Asset Management Inc. now owns 9,284 shares of the healthcare conglomerate’s stock valued at $1,724,000 after buying an additional 1,295 shares during the last quarter. 86.21% of the stock is owned by hedge funds and other institutional investors.

UnitedHealth Group Company Profile

UnitedHealth Group Incorporated is a health and well-being company. The Company operates through four segments: UnitedHealthcare, OptumHealth, OptumInsight and OptumRx. It conducts its operations through two business platforms: health benefits operating under UnitedHealthcare and health services operating under Optum.

Analyst Recommendations for UnitedHealth Group (NYSE:UNH)

Receive News & Ratings for UnitedHealth Group Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UnitedHealth Group Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.